AstraZeneca PLC and Perrigo Company plc: SG&A Spending Patterns Compared

AstraZeneca vs. Perrigo: SG&A Spending Trends Unveiled

__timestamp	AstraZeneca PLC	Perrigo Company plc
Wednesday, January 1, 2014	13324000000	675200000
Thursday, January 1, 2015	11451000000	771800000
Friday, January 1, 2016	9739000000	1205500000
Sunday, January 1, 2017	10543000000	1146500000
Monday, January 1, 2018	10362000000	1125800000
Tuesday, January 1, 2019	11848000000	1166100000
Wednesday, January 1, 2020	11693000000	1175500000
Friday, January 1, 2021	15680000000	1111400000
Saturday, January 1, 2022	18955000000	1210100000
Sunday, January 1, 2023	18025000000	1274600000
Monday, January 1, 2024	20532000000

Cracking the code

SG&A Spending Patterns: AstraZeneca vs. Perrigo

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Over the past decade, AstraZeneca PLC and Perrigo Company plc have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses surged by approximately 35%, peaking in 2022. This increase reflects their aggressive market expansion and investment in new drug launches. In contrast, Perrigo's SG&A expenses grew by about 89% over the same period, indicating a steady yet more conservative growth strategy. Notably, AstraZeneca's SG&A expenses in 2023 were nearly 14 times higher than Perrigo's, highlighting their larger scale of operations. These trends underscore the diverse strategies employed by pharmaceutical giants in navigating market challenges and opportunities.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025